CytoMed Therapeutics GDTC
NASDAQ GDTC
$0.90 +0.06 (+6.75%)
At close: Oct 1, 2026 · 4:00 PM EDT

CytoMed Therapeutics (GDTC) Share-based Compensation (2023 - 2026)

Updated

CytoMed Therapeutics (GDTC) posted Share-based Compensation of -$930,564 for FY2025, compared with -$619,327 in FY2024.

Analysis

CytoMed Therapeutics (GDTC) Share-based Compensation (2023 - 2026) Analysis & Trends

Since FY2020, CytoMed Therapeutics has reported Share-based Compensation for 6 years.

  • The FY2025 figure stands as the lowest annual Share-based Compensation in data going back to FY2020.
  • Business Quant data shows GDTC's Share-based Compensation at -$619,327 in FY2024, -$454,143 in FY2023, -$210,657 in FY2022 and -$168,802 in FY2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 458.00 Mn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 166.00 Mn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 298.00 Mn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 165.00 Mn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 231.00 Mn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 249.00 Mn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 170.20 Mn
10 CytoMed Therapeutics 9.94 Mn -1.15 Mn - 455,709.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 455,709.00
Jun 30, 2025 423,613.00
Jun 30, 2024 347,473.00
Jun 30, 2023 300,728.00
API Access

CytoMed Therapeutics Share-based Compensation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation&ticker=GDTC&period=max&api_key=YOUR_API_KEY